Cullinan Therapeutics, Inc. (CGEM) stock
CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$10.19−1.16 (-10.22%)
Close on Nov 12, 2026Market cap $655.77MP/E –Yield –
Cullinan Therapeutics cash
Cash and short-term investments held at the end of each period.
Cullinan Therapeutics's cash was $289.60M at Sep 30, 2026. For fiscal 2025 it was $377.90M, down 5.3% from the year before. The highest annual figure on record is $467.29M in fiscal 2022.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $377.90M | -5.3% |
| FY2024 | Dec 31, 2024 | $399.00M | -14.6% |
| FY2023 | Dec 31, 2023 | $467.07M | -0.0% |
| FY2022 | Dec 31, 2022 | $467.29M | +60.9% |
| FY2021 | Dec 31, 2021 | $290.47M | +38.2% |
| FY2020 | Dec 31, 2020 | $210.21M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $289.60M | -12.9% |
| Q2 FY2026 | Jun 30, 2026 | $334.50M | +26.0% |
| Q1 FY2026 | Mar 31, 2026 | $351.90M | +15.8% |
| Q4 FY2025 | Dec 31, 2025 | $377.90M | -5.3% |
| Q3 FY2025 | Sep 30, 2025 | $332.60M | -42.5% |
| Q2 FY2025 | Jun 30, 2025 | $265.50M | -59.9% |
| Q1 FY2025 | Mar 31, 2025 | $303.80M | -29.8% |
| Q4 FY2024 | Dec 31, 2024 | $399.00M | -14.6% |
| Q3 FY2024 | Sep 30, 2024 | $578.10M | +23.9% |
| Q2 FY2024 | Jun 30, 2024 | $662.50M | +34.7% |
| Q1 FY2024 | Mar 31, 2024 | $433.01M | +10.8% |
| Q4 FY2023 | Dec 31, 2023 | $467.07M | -0.0% |
| Q3 FY2023 | Sep 30, 2023 | $466.43M | -19.0% |
| Q2 FY2023 | Jun 30, 2023 | $491.80M | -19.5% |
| Q1 FY2023 | Mar 31, 2023 | $390.70M | +24.1% |
| Q4 FY2022 | Dec 31, 2022 | $467.29M | +60.9% |
| Q3 FY2022 | Sep 30, 2022 | $575.95M | +79.4% |
| Q2 FY2022 | Jun 30, 2022 | $611.00M | +81.5% |
| Q1 FY2022 | Mar 31, 2022 | $314.85M | -28.6% |
| Q4 FY2021 | Dec 31, 2021 | $290.47M | +38.2% |
| Q3 FY2021 | Sep 30, 2021 | $321.04M | – |
| Q2 FY2021 | Jun 30, 2021 | $336.71M | – |
| Q1 FY2021 | Mar 31, 2021 | $440.87M | – |
| Q4 FY2020 | Dec 31, 2020 | $210.21M | – |
See a number that looks wrong?